Monopar (MNPR) Director Raymond Anderson Sells 3,142 Shares

What Happened Raymond Anderson, a director of Monopar Therapeutics (MNPR), sold a total of 3,142 shares in open-market transactions on August 25, 2026, generating roughly $351,189 in proceeds. The reporting shows three reported lots: 694 shares at a weighted-average price of $110.04 ($76,368), 646 shares at $110.07 ($71,105), and 1,802 shares at $113.05 ($203,716). The filer notes these sales were made pursuant to a Rule 10b5-1 trading plan established on May 26, 2026.

Key Details

• Transaction date: 2026-08-25; Form 4 filed 2026-08-27 (appears timely).
• Lots reported: 694 @ $110.04 ($76,368), 646 @ $110.07 ($71,105), 1,802 @ $113.05 ($203,716); total proceeds ≈ $351,189.
• Price details: each reported price is a weighted average; footnotes disclose per-trade price ranges of $109.51–$110.43, $110.56–$111.41, and $112.84–$113.11. The reporting person will provide a detailed breakdown by price on request.
• Footnote: Transaction effected pursuant to a Rule 10b5-1 plan executed 05/26/2026.
• Shares owned after the transaction: not disclosed in the provided filing excerpt.
• Filing timeliness: filed within two business days of the trades (no late filing flag shown).

Context

• Sales under a 10b5-1 plan are pre-arranged and typically routine, and do not necessarily indicate a change in the insider’s view of the company. For retail investors, purchases are generally more indicative of insider confidence than scheduled sales. If you want the exact per-trade price breakdown, the filer has committed to provide those details to Monopar, any stockholder, or the SEC staff upon request.